An emerging direction in glucagon-based therapy
- PMID: 36323231
- DOI: 10.1016/j.cmet.2022.10.004
An emerging direction in glucagon-based therapy
Abstract
Glucagon receptor (GCGR) is an essential regulator of hepatic metabolism. In this issue of Cell Metabolism, Sekar et al. report that the endosomal protein Vps37a uncouples hepatic glucose production from lipid metabolism by altering the intracellular localization of GCGR, thereby providing a new potential therapeutic direction for type 2 diabetes.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no conflicts of interest.
Comment on
-
Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes.Cell Metab. 2022 Nov 1;34(11):1824-1842.e9. doi: 10.1016/j.cmet.2022.09.022. Epub 2022 Oct 14. Cell Metab. 2022. PMID: 36243006
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical